How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

In my experience, trying to discuss incidence rates and hazard ratios with patients is usually met with a response such as, “So what does this mean for me?” Translating the incidence rates into the number needed to harm (NNH) provides objective numbers which are easier for them to understand. Treati...

This is challenging. I wish we had tools to provide this information in easily digestible format for the patient in a busy clinic. I hope that the drug makers will work with experts to produce such tools, which can be unbiased and help providers and patients with this discussion. In the absence of s...